MX357648B - Vacuna antitumoral. - Google Patents

Vacuna antitumoral.

Info

Publication number
MX357648B
MX357648B MX2015002578A MX2015002578A MX357648B MX 357648 B MX357648 B MX 357648B MX 2015002578 A MX2015002578 A MX 2015002578A MX 2015002578 A MX2015002578 A MX 2015002578A MX 357648 B MX357648 B MX 357648B
Authority
MX
Mexico
Prior art keywords
cancer
relapse
cancer disease
tumor vaccination
kill
Prior art date
Application number
MX2015002578A
Other languages
English (en)
Other versions
MX2015002578A (es
Inventor
Andocs Gabor
Szász Olivér
Szász András
Iluri Nora
Original Assignee
Xax Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xax Kft filed Critical Xax Kft
Publication of MX2015002578A publication Critical patent/MX2015002578A/es
Publication of MX357648B publication Critical patent/MX357648B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
    • A61M2037/0007—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin having means for enhancing the permeation of substances through the epidermis, e.g. using suction or depression, electric or magnetic fields, sound waves or chemical agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medical Informatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a una vacuna compuesta de al menos un estimulante inmune y ondas de radiofrecuencia utilizando acoplamiento capacitivo, y con un método, especialmente, un método de vacunación in vivo e in situ para el tratamiento del cáncer primario y su metástasis aun en estados celulares diseminados, que no pueden ser detectados por los métodos de imagenología disponibles actualmente o para la prevención de la recaída en el cáncer, y especialmente, para habilitar y apoyar al sistema inmune propio del paciente para reconocer y matar a las células cancerosas y generar una memoria para prevenir la recaída en un cáncer.
MX2015002578A 2012-08-26 2013-08-26 Vacuna antitumoral. MX357648B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12181821.5A EP2703001A1 (en) 2012-08-26 2012-08-26 Tumor vaccination
US201261744008P 2012-09-17 2012-09-17
PCT/EP2013/067653 WO2014033097A1 (en) 2012-08-26 2013-08-26 Tumor vaccination

Publications (2)

Publication Number Publication Date
MX2015002578A MX2015002578A (es) 2015-06-10
MX357648B true MX357648B (es) 2018-07-18

Family

ID=46785268

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002578A MX357648B (es) 2012-08-26 2013-08-26 Vacuna antitumoral.

Country Status (13)

Country Link
US (1) US10792483B2 (es)
EP (2) EP2703001A1 (es)
JP (1) JP2015530379A (es)
KR (1) KR101714281B1 (es)
CN (1) CN104640553A (es)
AU (1) AU2013307344B2 (es)
CA (1) CA2879739C (es)
ES (1) ES2586234T3 (es)
HU (1) HUE030407T2 (es)
MX (1) MX357648B (es)
RU (1) RU2015110690A (es)
SG (1) SG11201500396TA (es)
WO (1) WO2014033097A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2703001A1 (en) 2012-08-26 2014-03-05 XAX Kft. Tumor vaccination
US11759650B2 (en) 2013-03-11 2023-09-19 NeuroEM Therapeutics, Inc. Immunoregulation, brain detoxification, and cognitive protection by electromagnetic treatment
US11813472B2 (en) 2013-03-11 2023-11-14 NeuroEM Therapeutics, Inc. Systems for sensing proper emitter array placement
US11911629B2 (en) 2013-03-11 2024-02-27 NeurEM Therapeutics, Inc. Treatment of primary and metastatic brain cancers by transcranial electromagnetic treatment
US11752356B2 (en) 2013-03-11 2023-09-12 NeuroEM Therapeutics, Inc. Systems for controlling power to differently loaded antenna arrays
CN104491464A (zh) * 2014-11-18 2015-04-08 四川金堂海纳生物医药技术研究所 一种治疗舌体干裂症的内服药物及制备方法
EP4026849A1 (en) * 2016-09-26 2022-07-13 Ensemble Group Holdings Methods of assessing and treating cancer in subjects having dysregulated lymphatic systems using a combination of vegfr-3 and pd-1 or pd-l1 inhibitors
KR101856904B1 (ko) * 2017-07-28 2018-05-11 동아대학교 산학협력단 Pauf 단백질에 특이적으로 결합하는 항체 및 이의 용도
AU2019255327A1 (en) * 2018-04-18 2020-11-12 Biomadison, Inc. Methods for determining vaccine potency
WO2020198145A1 (en) * 2019-03-22 2020-10-01 The Johns Hopkins University Gene delivery particles to induce tumor-derived antigen presenting cells
RU2722268C1 (ru) * 2019-12-06 2020-05-28 Федеральное государственное автономное образовательное учреждение высшего образования «Дальневосточный федеральный университет» (ДВФУ) Способ биотерапии лабораторных крыс с перевитой глиобластомой

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57130920A (en) * 1981-02-09 1982-08-13 Zenyaku Kogyo Kk Antitumor agent and its preparation
JPS58157706A (ja) * 1982-03-12 1983-09-19 Norin Suisansyo Kajiyu Shikenjo 果樹の摘花剤
JPS5936619A (ja) * 1982-08-23 1984-02-28 Tsumura Juntendo Inc 制癌補助剤
US4712559A (en) * 1985-06-28 1987-12-15 Bsd Medical Corporation Local current capacitive field applicator for interstitial array
US5099756A (en) * 1989-06-01 1992-03-31 Harry H. Leveen Radio frequency thermotherapy
US7429471B2 (en) * 2000-02-23 2008-09-30 The Trustees Of The University Of Pennsylvania Regulation of matrix metalloproteinase gene expression using specific and selective electrical and electromagnetic signals
US6904323B2 (en) 2003-05-14 2005-06-07 Duke University Non-invasive apparatus and method for providing RF energy-induced localized hyperthermia
AU2006333978B2 (en) * 2006-01-06 2012-04-19 Cell-Medicine, Inc. Immune adjuvant
US8019414B2 (en) * 2006-04-05 2011-09-13 Novocure Ltd. Treating cancer using electromagnetic fields in combination with other treatment regimens
US20090018613A1 (en) * 2006-08-02 2009-01-15 Genestim, Llc Regulation of vascular endothelial growth factor (vegf) gene expression in tissue via the application of electric and/or electromagnetic fields
DE102006050369A1 (de) * 2006-10-25 2008-04-30 Oncotherm Kft. Hyperthermievorrichtung für die selektive Behandlung und die Überwachung von Oberflächengewebe
EP2245047B1 (en) 2008-01-25 2020-11-18 Ruprecht-Karls-Universität Heidelberg Hydrophobic modified pres-derived peptides of hepatitis b virus (hbv) and their use as vehicles for the specific delivery of compounds to the liver
EP2082777A1 (en) 2008-01-27 2009-07-29 Oncotherm Kft. Flexible and porous large-area electrode for heating
EP2153866A1 (en) * 2008-08-14 2010-02-17 Oncotherm Kft. Portable radiofrequency hyperthermia device with flexible treatment electrode for electric field capacitive coupled energy transfer
EP2174689A1 (en) 2008-10-13 2010-04-14 Oncotherm Kft. Radiofrequency hyperthermia device with target feedback signal modulation
EP2177336A1 (en) 2008-10-17 2010-04-21 Grupo Antolin-Ingenieria, S.A. Method for manufacturing a vehicle trim panel
GB2476315A (en) 2009-12-21 2011-06-22 Rec Wafer Norway As Cleaning a stack of thin wafers
US9162075B2 (en) * 2009-12-23 2015-10-20 Hitops Gmbh Use of pulsed radio frequency
EP2703001A1 (en) 2012-08-26 2014-03-05 XAX Kft. Tumor vaccination

Also Published As

Publication number Publication date
HUE030407T2 (en) 2017-05-29
WO2014033097A1 (en) 2014-03-06
KR101714281B1 (ko) 2017-03-09
CA2879739A1 (en) 2014-03-06
US10792483B2 (en) 2020-10-06
CA2879739C (en) 2017-01-31
EP2780024A1 (en) 2014-09-24
ES2586234T3 (es) 2016-10-13
MX2015002578A (es) 2015-06-10
AU2013307344A1 (en) 2015-02-26
KR20150043375A (ko) 2015-04-22
EP2780024B1 (en) 2016-05-25
RU2015110690A (ru) 2016-10-20
US20150217099A1 (en) 2015-08-06
CN104640553A (zh) 2015-05-20
JP2015530379A (ja) 2015-10-15
SG11201500396TA (en) 2015-02-27
EP2703001A1 (en) 2014-03-05
AU2013307344B2 (en) 2016-08-25

Similar Documents

Publication Publication Date Title
MX357648B (es) Vacuna antitumoral.
ZA201907607B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MX2017003246A (es) Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer.
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
MX2021008224A (es) Combinacion de vacunacion e inhibicion de la trayectoria pd-1.
PH12017502142A1 (en) Tetrasubstituted aklene compounds and their use
IL248164A0 (en) 3D engineered breast tissue and adipose tissue, and a tumor disease model
MX2021003858A (es) Conjugados para el tratamiento de enfermedades causadas por celulas que expresan psma.
RS20140202A1 (en) BIOSPECIFIC IMMUNOVELING PROTEINS DIRECTED AGAINST TNF AND IL-17
PT4095130T (pt) Inibidores marcados do antígeno de membrana específico da próstata (psma), seu uso como agentes de imagem e agentes farmacêuticos para o tratamento do cancro da próstata
MX2013007657A (es) Oligodesoxinucleotidos inmunoestimulantes.
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
EA201692100A8 (ru) Новые антитела против rnf43 и способы их применения
MY179105A (en) Methods of treating alzheimer's disease
MX2013013801A (es) Oligodesoxinucleotidos inmunoestimuladores.
MA40458A (fr) Méthodes de traitement du cancer du col de l'utérus
CA2888908A1 (en) Antibodies against kidney associated antigen 1 and antigen binding fragments thereof
WO2014200969A3 (en) Methods of treatment of cancer
EA201891419A1 (ru) Пептид-олигонуклеотидные конъюгаты
MX2016004212A (es) Inhibidor de tor cinasa en la prevencion o tratamiento de cancer caracterizado por mutaciones genicas.
WO2010144846A3 (en) Gastrointestinal disease or disorder imaging and treatment
EP2879705A4 (en) PEPTIDE VACCINES BASED ON THE EGFRVIII SEQUENCE FOR THE TREATMENT OF TUMORS
PH12014502464A1 (en) Veliparib in combination with whole brain radiation therapy for the treatment of brain metastases
WO2014186596A3 (en) Correlates of efficacy relating to tumor vaccines
CY1119845T1 (el) Ενα γαλακτοκομικο προϊον μειωμενης χοληστερολης για χρηση στην θεραπευτικη αντιμετωπιση και/ή προληψη μιας ασθενειας του ηπατος

Legal Events

Date Code Title Description
FG Grant or registration